Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSXNASDAQ:BRTXNASDAQ:OPGNNASDAQ:PIII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$0.29-4.4%$0.42$0.17▼$2.04$42.02M0.992.42 million shs740,169 shsBRTXBioRestorative Therapies$1.68-16.0%$1.75$1.21▼$2.55$12.61M76.75176,007 shs667,742 shsOPGNOpGen$4.94-0.4%$4.64$0.53▼$5.25$49.74M-1.689,587 shs1,185 shsPIIIP3 Health Partners$6.44+1.4%$8.06$6.20▼$33.73$46.28M0.8420,231 shs1,232 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix-4.40%-5.35%+30.32%-60.30%-81.38%BRTXBioRestorative Therapies-16.00%-6.93%-1.75%-5.08%+24.44%OPGNOpGen-0.40%+5.11%+5.11%+280.00%+93.73%PIIIP3 Health Partners+1.40%-2.73%-21.28%-26.37%-79.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSXBiodesix3.5026 of 5 stars4.42.00.00.02.92.50.6BRTXBioRestorative Therapies3.9334 of 5 stars3.55.00.00.02.73.31.3OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.2968 of 5 stars3.34.00.00.01.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.80Moderate Buy$1.75510.39% UpsideBRTXBioRestorative Therapies 3.00Buy$18.00971.43% UpsideOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25152.37% UpsideCurrent Analyst Ratings BreakdownLatest BRTX, BDSX, OPGN, and PIII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.005/14/2025BDSXBiodesixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $2.005/14/2025BDSXBiodesixCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.505/14/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $1.505/14/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform4/29/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.504/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$74.46M0.56N/AN/A$0.05 per share5.73BRTXBioRestorative Therapies$391K32.25N/AN/A$2.45 per share0.69OPGNOpGen$2.67M18.61N/AN/A($11.55) per share-0.43PIIIP3 Health Partners$1.49B0.03$2.78 per share2.32$0.45 per share14.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$52.15M-$0.29N/AN/AN/A-66.84%-275.79%-43.05%8/6/2025 (Estimated)BRTXBioRestorative Therapies-$14.41M-$1.47N/AN/AN/A-2,697.08%-98.49%-75.23%8/12/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)Latest BRTX, BDSX, OPGN, and PIII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million5/14/2025Q1 2025BRTXBioRestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million5/13/2025Q1 2025BDSXBiodesix-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million3/27/2025Q4 2024BRTXBioRestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ABRTXBioRestorative TherapiesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix1.303.403.40BRTXBioRestorative TherapiesN/A2.952.95OPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%BRTXBioRestorative Therapies69.38%OPGNOpGen2.68%PIIIP3 Health Partners7.75%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix30.10%BRTXBioRestorative Therapies25.50%OPGNOpGen43.80%PIIIP3 Health Partners17.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix220146.56 million44.80 millionOptionableBRTXBioRestorative Therapies77.51 million5.16 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.19 million294.74 millionNot OptionableBRTX, BDSX, OPGN, and PIII HeadlinesRecent News About These CompaniesBears are Losing Control Over P3 Health Partners (PIII), Here's Why It's a 'Buy' NowJune 12 at 10:56 AM | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 6, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.June 3, 2025 | globenewswire.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 27, 2025 | globenewswire.comDown 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)May 26, 2025 | zacks.comWolf Haldenstein Adler Freeman & Herz LLP is investigating P3 Health Partners, Inc.May 23, 2025 | globenewswire.comP3 Health Partners Inc. (NASDAQ:PIII) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Report Preview: What To Look ForMay 16, 2025 | finance.yahoo.comP3 Health Partners Inc (PIII) Q1 2025 Earnings Call Highlights: Strategic Adjustments and ...May 16, 2025 | finance.yahoo.comP3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025May 16, 2025 | msn.comP3 Health Partners Inc. (PIII) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comP3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comP3 Health Partners Announces First Quarter 2025 ResultsMay 15, 2025 | businesswire.comP3 Health Partners (NASDAQ:PIII) Stock Price Down 3% - Here's What HappenedMay 15, 2025 | marketbeat.comP3 Health Partners price target lowered to $20 from $50 at Lake StreetApril 21, 2025 | markets.businessinsider.comP3 Health Partners (PIII) Stock Jumps 8.9%: Will It Continue to Soar?April 16, 2025 | zacks.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Earnings Estimates, EPS & Revenue | NASDAQ:PIII | BenzingaApril 15, 2025 | benzinga.comP3 Health Partners Inc trading halted, news pendingApril 12, 2025 | markets.businessinsider.comP3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | businesswire.comP3 Health Partners (PIII) Gets a Hold from TD CowenMarch 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRTX, BDSX, OPGN, and PIII Company DescriptionsBiodesix NASDAQ:BDSX$0.29 -0.01 (-4.40%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+1.15%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.BioRestorative Therapies NASDAQ:BRTX$1.68 -0.32 (-16.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.68 0.00 (-0.06%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.OpGen NASDAQ:OPGN$4.94 -0.02 (-0.40%) As of 06/13/2025 10:53 AM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$6.44 +0.09 (+1.40%) Closing price 06/13/2025 03:57 PM EasternExtended Trading$6.48 +0.04 (+0.56%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
